Skip to content

Kaiser Permanente Mid-Atlantic

Does Kaiser Permanente Mid-Atlantic cover Zepbound for Obstructive Sleep Apnea (OSA)?

Yes. Kaiser Permanente Mid-Atlantic covers Zepbound for obstructive sleep apnea (OSA) with prior authorization if your BMI is 35 or higher. Other policy requirements and your plan's benefits also apply.

Policy document

  • Hmo Exchange Prior Authorization Criteria En

    Kaiser Permanente Mid-Atlantic · PA policy · Employer, ACA Marketplace, and Federal Employee Program

    Effective June 2, 2026. Verified June 5, 2026.

    View PDF Download Original insurer source
  • Employer, ACA Marketplace, and Federal Employee Program: Covered with requirements. See the qualification pathways below.

Earliest policy review June 5, 2026. How we verify · Check your exact plan

Full requirements: Zepbound for Obstructive Sleep Apnea (OSA) (3 plan types)

Applies to Employer, ACA Marketplace, and Federal Employee Program plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

OSA — BMI ≥50 (no prior GLP-1 step therapy required at this BMI tier)

All of:

  • Moderate-to-severe OSA diagnosis: moderate OSA by polysomnography within past year with AHI 15-29, OR severe OSA with AHI ≥30
  • PAP therapy: unable to use PAP therapy (documented anxiety with use, documented nasal/oral discomfort preventing adequate sleep, etc.) OR if able to use PAP, must have used for at least 3 months and plan to continue
  • Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Pulmonologist or Weight Management Specialist
  • Age ≥ 18 years
  • Documented baseline weight within past 30 days
  • Actively adhering to prescriber-documented lifestyle interventions (90 days with nutrition and physical activity components) and will continue
  • Baseline BMI ≥50 kg/m2
  • Not currently prescribed another GLP-1 RA or GIP/GLP-1 RA
  • No reasons for non-coverage (T1D or T2D; central or mixed sleep apnea; prior or planned surgical/minimally invasive treatment for OSA or obesity; significant renal/pulmonary/liver disease; other comorbidities or medications affecting weight or daytime sleepiness; prior acute or chronic pancreatitis; personal or family history of MTC or MEN2)

OSA — BMI 35 to <50 (requires prior GLP-1 step therapy)

All of:

  • Moderate-to-severe OSA diagnosis: moderate OSA by polysomnography within past year with AHI 15-29, OR severe OSA with AHI ≥30
  • PAP therapy: unable to use PAP therapy (documented anxiety with use, documented nasal/oral discomfort preventing adequate sleep, etc.) OR if able to use PAP, must have used for at least 3 months and plan to continue
  • Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Pulmonologist or Weight Management Specialist
  • Age ≥ 18 years
  • Documented baseline weight within past 30 days
  • Actively adhering to prescriber-documented lifestyle interventions (90 days with nutrition and physical activity components) and will continue
  • Baseline BMI ≥35 to <50 kg/m2
  • Documented intolerance, contraindication, or failure to lose and maintain ≥5% body weight after 3-month trial at maximum tolerated dose of Wegovy (or liraglutide for overweight or obesity, followed by semaglutide for overweight or obesity)
  • Not currently prescribed another GLP-1 RA or GIP/GLP-1 RA
  • No reasons for non-coverage (T1D or T2D; central or mixed sleep apnea; prior or planned surgical/minimally invasive treatment for OSA or obesity; significant renal/pulmonary/liver disease; other comorbidities or medications affecting weight or daytime sleepiness; prior acute or chronic pancreatitis; personal or family history of MTC or MEN2)

Documentation to bring

  • Moderate-to-severe OSA diagnosis confirmed by polysomnography within past year (AHI 15-29 for moderate, AHI ≥30 for severe)
  • Documentation of PAP therapy status: either inability to use PAP (documented anxiety, nasal/oral discomfort) OR documentation of PAP use for at least 3 months with plan to continue
  • Referral through Pharmacy Review – Injectable Weight Loss OR documentation that prescriber is a Pulmonologist or Weight Management Specialist
  • Patient age documentation (≥18 years)
  • Documented baseline weight within past 30 days
  • Documented baseline BMI
  • Prescriber-documented lifestyle interventions with nutrition and physical activity components (90 days)
  • For BMI 35 to <50: documentation of intolerance, contraindication, or failure to lose/maintain ≥5% body weight after 3-month trial at maximum tolerated dose of Wegovy (or liraglutide for overweight/obesity followed by semaglutide for overweight/obesity)
  • Confirmation patient is not currently prescribed another GLP-1 RA or GIP/GLP-1 RA
  • Confirmation of absence of all reasons for non-coverage (T1/T2DM, central/mixed sleep apnea, prior/planned surgical treatment for OSA or obesity, significant renal/pulmonary/liver disease, other relevant comorbidities/medications, pancreatitis history, MTC/MEN2 history)

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • Renewal: 25% improvement in AHI from baseline. Must continue actively adhering to prescriber-documented lifestyle interventions (with nutrition and physical activity components). BMI ≥27 kg/m2 required. No reasons for non-coverage. Baseline BMI is explicitly NOT re-evaluated at continuation — policy states 'do not consider baseline BMI over the course of treatment; baseline BMI was considered when this therapy course was initially approved.'.

Not covered when

  • Type 2 diabetes
  • Central or mixed sleep apnea
  • Prior or planned surgical or minimally invasive treatment for OSA or obesity
  • Significant renal, pulmonary, or liver disease
  • Other comorbidities or medications that may affect weight or daytime sleepiness
  • Prior acute or chronic pancreatitis
  • Personal or family history of MTC or MEN2
  • Currently prescribed another GLP-1 RA or GIP/GLP-1 RA
  • Type 1 diabetes

Policy note: OSA indication applies to Zepbound ONLY. Polysomnography must be within the past year. Moderate OSA: AHI 15-29; severe OSA: AHI ≥30. PAP therapy requirement: patient must either be unable to use PAP OR have used PAP for at least 3 months (and plan to continue). For BMI ≥50: no prior GLP-1 step therapy required. For BMI 35 to <50: requires prior failure of Wegovy (or liraglutide for obesity followed by semaglutide for obesity) — 3-month trial at maximum tolerated dose. Note: policy states that if liraglutide or semaglutide are prescribed for OSA indication, Zepbound's OSA criteria will be applied. Continuation: baseline BMI explicitly not re-evaluated; continuation based on 25% AHI improvement, lifestyle adherence, BMI ≥27, and no reasons for non-coverage. Exclusions are based on SURMOUNT-OSA trial exclusion criteria.

Policy effective June 2, 2026 · verified June 5, 2026 · source: Hmo Exchange Prior Authorization Criteria En · View policy document (PDF)

Open on its own page →

Questions people ask
Does Kaiser Permanente Mid-Atlantic cover Zepbound?
Yes. Kaiser Permanente Mid-Atlantic covers Zepbound for obstructive sleep apnea (OSA) with prior authorization if your BMI is 35 or higher. Other policy requirements and your plan's benefits also apply.
How long does a Zepbound approval last with Kaiser Permanente Mid-Atlantic?
Obstructive Sleep Apnea (OSA) — Applies to Employer, ACA Marketplace, and Federal Employee Program plans. Initial approval: 6 months. Renewal: every 6 months.
What does Kaiser Permanente Mid-Atlantic require to renew Zepbound?
Obstructive Sleep Apnea (OSA) — Applies to Employer, ACA Marketplace, and Federal Employee Program plans. 25% improvement in AHI from baseline. Must continue actively adhering to prescriber-documented lifestyle interventions (with nutrition and physical activity components). BMI ≥27 kg/m2 required. No reasons for non-coverage. Baseline BMI is explicitly NOT re-evaluated at continuation — policy states 'do not consider baseline BMI over the course of treatment; baseline BMI was considered when this therapy course was initially approved.'.
How current is this information?
The oldest review date among the policies on this page is June 5, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under Kaiser Permanente Mid-Atlantic: Mounjaro, Ozempic, Wegovy

Zepbound under other plans: Elevance Health, Maryland Medicaid, Virginia Medicaid, Alabama Medicaid, California Medicaid, Colorado Medicaid, Connecticut Medicaid, Delaware Medicaid

All insurance plans · All medications

Summary of Kaiser Permanente Mid-Atlantic's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.